$BLUE
bluebird bio, Inc.

2015 Q1 Form 10-K Financial Statement

#000156459015000948 Filed on February 25, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q3
Revenue $6.344M $6.386M $6.365M
YoY Change 0.14% 0.81% -0.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.300M $5.300M $6.600M
YoY Change 32.73% 12.77% 73.68%
% of Gross Profit
Research & Development $23.72M $20.50M $16.65M
YoY Change 106.92% 109.18% 91.24%
% of Gross Profit
Depreciation & Amortization $1.710M $1.670M $1.540M
YoY Change 256.25% 406.06% 396.77%
% of Gross Profit
Operating Expenses $31.27M $25.80M $16.65M
YoY Change 83.91% 77.93% 91.24%
Operating Profit -$24.93M -$19.61M -$17.01M
YoY Change 133.65% 141.7% 176.27%
Interest Expense -$200.0K -$200.0K -$100.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $139.0K $100.0K -$20.00K
YoY Change 135.59% -145.45%
Pretax Income -$24.79M -$19.50M -$17.03M
YoY Change 133.84% 140.74% 178.59%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.79M -$19.54M -$17.03M
YoY Change 133.64% 141.85% 178.59%
Net Earnings / Revenue -390.72% -306.04% -267.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$760.7K -$663.3K -$605.0K
COMMON SHARES
Basic Shares Outstanding 32.57M 28.82M 28.60M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $334.9M $473.6M $215.4M
YoY Change 73.97% 129.59% -0.65%
Cash & Equivalents $133.2M $347.8M $89.60M
Short-Term Investments $201.7M $125.7M $125.8M
Other Short-Term Assets $5.900M $6.400M $7.900M
YoY Change 73.53% 12.28% 68.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $340.8M $480.0M $223.3M
YoY Change 73.97% 126.42% 0.84%
LONG-TERM ASSETS
Property, Plant & Equipment $16.85M $15.74M $14.98M
YoY Change 40.6% 44.14% 177.78%
Goodwill $13.13M $13.13M $13.13M
YoY Change
Intangibles $27.28M $28.22M $29.16M
YoY Change
Long-Term Investments $134.4M $18.40M $48.40M
YoY Change
Other Assets $1.294M $1.215M $1.162M
YoY Change -19.13% -18.07% -17.0%
Total Long-Term Assets $193.0M $76.75M $106.9M
YoY Change 1320.01% 518.8% 1472.82%
TOTAL ASSETS
Total Short-Term Assets $340.8M $480.0M $223.3M
Total Long-Term Assets $193.0M $76.75M $106.9M
Total Assets $533.8M $556.7M $330.2M
YoY Change 154.79% 148.11% 44.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.551M $2.954M $3.641M
YoY Change -1.92% -32.23% 218.27%
Accrued Expenses $15.10M $12.70M $9.700M
YoY Change 190.38% 159.18% 94.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.01M $42.98M $38.52M
YoY Change 27.13% 23.24% 22.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $265.0K $294.0K $323.0K
YoY Change -31.17% 41.35% -99.17%
Total Long-Term Liabilities $265.0K $294.0K $323.0K
YoY Change -31.17% 41.35% -99.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.01M $42.98M $38.52M
Total Long-Term Liabilities $265.0K $294.0K $323.0K
Total Liabilities $59.32M $65.48M $68.30M
YoY Change -9.22% -9.96% -3.2%
SHAREHOLDERS EQUITY
Retained Earnings -$172.2M -$147.4M -$127.8M
YoY Change 57.54% 49.36% 41.11%
Common Stock $327.0K $323.0K $287.0K
YoY Change 34.57% 35.15% 21.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $474.5M $491.3M $261.9M
YoY Change
Total Liabilities & Shareholders Equity $533.8M $556.7M $330.2M
YoY Change 154.79% 148.11% 44.66%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$24.79M -$19.54M -$17.03M
YoY Change 133.64% 141.85% 178.59%
Depreciation, Depletion And Amortization $1.710M $1.670M $1.540M
YoY Change 256.25% 406.06% 396.77%
Cash From Operating Activities -$24.16M -$15.66M -$20.77M
YoY Change 102.51% 186.81% 134.42%
INVESTING ACTIVITIES
Capital Expenditures $1.156M -$2.410M -$1.770M
YoY Change -54.07% -54.44% -16.11%
Acquisitions
YoY Change
Other Investing Activities -$191.8M $30.00M -$173.8M
YoY Change -173920.0%
Cash From Investing Activities -$193.0M $27.60M -$175.6M
YoY Change 7557.94% -621.74% 8635.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.464M
YoY Change 267.21%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.460M 246.3M 110.2M
YoY Change 267.16% 106991.3% -9442.37%
NET CHANGE
Cash From Operating Activities -24.16M -15.66M -20.77M
Cash From Investing Activities -193.0M 27.60M -175.6M
Cash From Financing Activities 2.460M 246.3M 110.2M
Net Change In Cash -214.7M 258.3M -86.11M
YoY Change 1457.91% -2554.85% 614.61%
FREE CASH FLOW
Cash From Operating Activities -$24.16M -$15.66M -$20.77M
Capital Expenditures $1.156M -$2.410M -$1.770M
Free Cash Flow -$25.32M -$13.25M -$19.00M
YoY Change 75.23% 7694.12% 181.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32566331
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
347845000
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
125710000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23940000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-71000
CY2013 us-gaap Contracts Revenue
ContractsRevenue
19792000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
323000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23940000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
638389000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98675000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
151667000
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-60626000
CY2014 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2014Q2 dei Entity Public Float
EntityPublicFloat
798893699
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
120000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-60506000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-25321000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2012 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
13000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-24947000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-23716000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
152000
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1913000
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
693000
CY2014Q4 blue Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14649000
CY2013Q4 blue Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5175000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1913000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147384000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
491257000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
86047000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
556739000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
45128000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
24056000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
440000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32340000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32340000
CY2014 us-gaap Contracts Revenue
ContractsRevenue
25031000
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-28000
CY2014 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
131000
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-163000
CY2013 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
37000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23227000
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
246000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
294000
CY2014Q4 us-gaap Liabilities
Liabilities
65482000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
224390000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23671000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-23670000
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-71000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25321000
CY2012 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3057000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-23114000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48709000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25321000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3613000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-55707000
CY2012 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3057000
CY2012 blue Gain Loss On Extinguishment Of Convertible Preferred Stock
GainLossOnExtinguishmentOfConvertiblePreferredStock
23114000
CY2012 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2337000
CY2012 blue Reclassification Of Convertible Preferred Stock Warrants To Common Stock Warrants
ReclassificationOfConvertiblePreferredStockWarrantsToCommonStockWarrants
394000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2012 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
822000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-55747000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11229000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
23295000
CY2013 blue Proceeds From Initial Public Offering
ProceedsFromInitialPublicOffering
-104921000
CY2013 blue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
-119841000
CY2013 blue Reclassification Of Convertible Preferred Stock Warrants To Common Stock Warrants
ReclassificationOfConvertiblePreferredStockWarrantsToCommonStockWarrants
655000
CY2013 blue Adjustments To Additional Paid In Capital Repayment Of Nonrecourse Note
AdjustmentsToAdditionalPaidInCapitalRepaymentOfNonrecourseNote
344000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
483000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6491000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
353042000
CY2014 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
19474000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5049000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
42000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10763000
CY2014 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-71000
CY2014 blue Noncash Benefit On Release Of Income Tax Valuation Allowance
NoncashBenefitOnReleaseOfIncomeTaxValuationAllowance
11797000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4228000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
941000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
301000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
10763000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
6491000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
822000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
168000
CY2014 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3000
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9000
CY2012 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-10000
CY2014 us-gaap Other Noncash Expense
OtherNoncashExpense
139000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-307000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8670000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
174981000
CY2013 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
761000
CY2012 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1336000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4214000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-93000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2249000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2067000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
380000
CY2014 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9969000
CY2014 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
2110000
CY2013 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
7408000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-24871000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
54868000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-340000
CY2012 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
52000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-59693000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
43450000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21044000
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-209000
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1153000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
40000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8708000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
867000
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30960000
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3506000
CY2014 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4673000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-157193000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9823000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2599000
CY2014 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
353226000
CY2013 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
104921000
CY2012 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
59831000
CY2013 us-gaap Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
344000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5226000
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
376000
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
358452000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
105641000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
59852000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
141566000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
139268000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41407000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67011000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25604000
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
387000
CY2013 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1924000
CY2014 blue Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
183000
CY2013 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
655000
CY2012 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
394000
CY2012 blue Reclassification Of Convertible Preferred Stock To Common Stock
ReclassificationOfConvertiblePreferredStockToCommonStock
2337000
CY2013 blue Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering
122178000
CY2014 blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
98000
CY2013 blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
107000
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company was formed to develop, manufacture and market therapies to safely and effectively deliver genes useful in the treatment of serious human diseases. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;30, 2014, the Company acquired all of the outstanding capital stock of Precision Genome Engineering, Inc. (&#8220;Pregenen&#8221;) and in connection therewith, obtained the rights to Pregenen&#8217;s gene editing and cell signaling technology. See Note 12, &#8220;Business combinations,&#8221; for additional information. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2014, the Company sold 3,450,000 shares of common stock (inclusive of 450,000 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $34.00 per share. The aggregate net proceeds received by the Company from the offering were $109.8 million, net of underwriting discounts and commissions and offering expenses payable by the Company of approximately $7.5 million. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company sold 3,047,500 shares of common stock (inclusive of 397,500 shares of common stock sold by the Company pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $85.00 per share. The aggregate net proceeds received by the Company from the offering were $243.3 million, net of underwriting discounts and commissions and estimated offering expenses payable by the Company of approximately $15.8 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2014, the Company had cash, cash equivalents and marketable securities of $492.0 million. Although the Company has incurred recurring losses, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months. </p></div>
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: acquisition-date fair value and subsequent fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes. </p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk and off-balance sheet risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s available-for-sale investments primarily consist of U.S. government agency securities and federally insured certificates of deposit and potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy which limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. </p></div>
CY2014Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
34.00
CY2014Q3 us-gaap Investment Banking Advisory Brokerage And Underwriting Fees And Commissions
InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
7500000
CY2014Q3 blue Stock Issued During Period Shares Overallotment Options Exercised
StockIssuedDuringPeriodSharesOverallotmentOptionsExercised
450000
CY2014Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3047500
CY2014Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
243300000
CY2014Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
85.00
CY2014Q4 us-gaap Investment Banking Advisory Brokerage And Underwriting Fees And Commissions
InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
15800000
CY2014Q4 blue Stock Issued During Period Shares Overallotment Options Exercised
StockIssuedDuringPeriodSharesOverallotmentOptionsExercised
397500
CY2014Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3450000
CY2014Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
109800000
CY2014Q4 blue Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
492000000
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2012 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 blue Collaborative Arrangement Term Of Agreement
CollaborativeArrangementTermOfAgreement
P2Y
CY2014 blue Collaborative Arrangement Term Of Extended Agreement
CollaborativeArrangementTermOfExtendedAgreement
P1Y
CY2014Q1 blue Tax Incentive Program Tax Incentive Awarded
TaxIncentiveProgramTaxIncentiveAwarded
300000
CY2014 blue Number Of New Employees Hired For Additional Headcount
NumberOfNewEmployeesHiredForAdditionalHeadcount
15
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
144229000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
77000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
144158000
CY2014Q4 us-gaap Available For Sale Securities And Held To Maturity Securities
AvailableForSaleSecuritiesAndHeldToMaturitySecurities
0
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
492003000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
6796000
CY2014 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2014 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2013 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
134400000
CY2014Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
475000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19141000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12374000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3401000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1454000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2300000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4943000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1740000
CY2013Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
2119000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
428000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
914000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
531000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
273000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
177000
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
338000
CY2012Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6512650
CY2014 blue Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
160676
CY2013 blue Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
102394
CY2014Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
7358000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
305000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
738000
CY2014 blue Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
0
CY2014Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2013Q2 blue Rent Abatement Credits
RentAbatementCredits
200000
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
6500000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013Q2 blue Letter Of Credit Related With New Lease Agreement
LetterOfCreditRelatedWithNewLeaseAgreement
1300000
CY2014 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-03-31
CY2014Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
1200000
CY2014Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9869
CY2014Q4 blue Additional Lease Rent Payable
AdditionalLeaseRentPayable
600000
CY2014Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-12
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3652000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3492000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3358000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3460000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
3563000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
11344000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
28869000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4300000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2400000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
800000
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stock are entitled to one vote per share
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4805000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3763000
CY2014Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
9404000
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28219000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10763000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6491000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
822000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.823
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.820
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.796
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
41400000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3900000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.53
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.36
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.51
CY2013Q3 us-gaap Revenues
Revenues
6385000
CY2013Q4 us-gaap Revenues
Revenues
6335000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6157000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8115000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-6113000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-8081000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2014Q4 blue Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Held By Former Employees
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesHeldByFormerEmployees
123263
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
600000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3957673
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1188060
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1313031
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
180465
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3652237
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1251045
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3597828
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.21
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
26.80
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.95
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.98
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.30
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.37
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.41
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
290049000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
109283000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
285358000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-61118000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-26018000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23700000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
612000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
697000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
30000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-9390000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2408000
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2014 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.032
CY2013 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.006
CY2012 blue Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.008
CY2014 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.257
CY2013 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.060
CY2012 blue Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.008
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.410
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.439
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.390
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
33767000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
11010000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
899000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
659000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
23274000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3638000
CY2014Q4 blue Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
1372000
CY2013Q4 blue Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
1837000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12050000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
21830000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
7552000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4177000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
78914000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43151000
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
11084000
CY2014Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2526000
CY2013Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2596000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
65304000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40555000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24700000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4108000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4365000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19185000
CY2014Q1 us-gaap Revenues
Revenues
6335000
CY2014Q2 us-gaap Revenues
Revenues
6335000
CY2014Q3 us-gaap Revenues
Revenues
6365000
CY2014Q4 us-gaap Revenues
Revenues
6386000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
17003000
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
19669000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
23375000
CY2014Q4 us-gaap Costs And Expenses
CostsAndExpenses
26000000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10668000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13334000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17010000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19614000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-10609000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1526000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-17030000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-19544000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2013Q1 us-gaap Revenues
Revenues
1127000
CY2013Q2 us-gaap Revenues
Revenues
6334000
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
7608000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
10528000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
12542000
CY2013Q4 us-gaap Costs And Expenses
CostsAndExpenses
14450000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6481000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4194000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-6544000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-4583000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.94
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.13
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11800000

Files In Submission

Name View Source Status
0001564590-15-000948-index-headers.html Edgar Link pending
0001564590-15-000948-index.html Edgar Link pending
0001564590-15-000948.txt Edgar Link pending
0001564590-15-000948-xbrl.zip Edgar Link pending
blue-10k_20141231.htm Edgar Link pending
blue-20141231.xml Edgar Link completed
blue-20141231.xsd Edgar Link pending
blue-20141231_cal.xml Edgar Link unprocessable
blue-20141231_def.xml Edgar Link unprocessable
blue-20141231_lab.xml Edgar Link unprocessable
blue-20141231_pre.xml Edgar Link unprocessable
blue-ex231_20141231355.htm Edgar Link pending
blue-ex311_201412318.htm Edgar Link pending
blue-ex312_201412319.htm Edgar Link pending
blue-ex321_2014123110.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g201502241949159075184.jpg Edgar Link pending
g201502241949159545185.jpg Edgar Link pending
g201502241949163295186.jpg Edgar Link pending
g201502241949217985187.jpg Edgar Link pending
g201502241949219545188.jpg Edgar Link pending
g201502241949372205189.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending